Table 2.
Baseline patient characteristics—Pre-weighting
| Parameter | N | N |
|---|---|---|
| Treatment | cTACE | DEB-TACE |
| Demographics | 95 | 38 |
| Age | ||
| >65 years | 28 (27.4 %) | 16 (42.1 %) |
| ≤65 years | 67 (72.6 %) | 22 (57.9 %) |
| Sex | ||
| Male | 85 (89.5 %) | 30 (78.9 %) |
| Female | 10 (10.5 %) | 8 (21.1 %) |
| Cirrhosis | ||
| Absent | 9 (9.5 %) | 6 (15.8 %) |
| Present | 86 (90.5 %) | 32 (84.2 %) |
| Staging System | ||
| BCLC class | ||
| C | 77 (81.1 %) | 32 (84.2 %) |
| D | 18 (18.9 %) | 6 (15.8 %) |
| ECOG PS score | ||
| 0 | 29 (31 %) | 6 (15.8 %) |
| 1 | 58 (61 %) | 25 (65.8 %) |
| 2 | 3 (3 %) | 4 (10.5 %) |
| 3 | 5 (5 %) | 3 (7.9 %) |
| Child Pugh class | ||
| A | 37 (39 %) | 18 (47.4 %) |
| B | 44 (46 %) | 17 (44.7 %) |
| C | 14 (15 %) | 3 (7.9 %) |
| Tumor characteristics | ||
| Portal Venous Thrombosis | ||
| peripheral | 22 (23.2 %) | 13 (34.2 %) |
| main | 33 (34.7 %) | 12 (31.6 %) |
| extrahepatic | 40 (42.1 %) | 13 (34.2 %) |
| Multiplicity | ||
| unifocal | 8 (8.4 %) | 8 (21.1 %) |
| multifocal | 87 (91.6 %) | 30 (78.9 % |
| Size of the dominant lesion (D | iameter) | |
| BCLC | ||
| ≤3 cm | 4 (4.2 %) | 2 (5.3 %) |
| >3 cm | 91 (95.8 %) | 36 (94.7 %) |
| Tumor burden | ||
| ≤50 % | 63 (66.3 %) | 27 (71.1 %) |
| >50 % | 32 (33.7 %) | 11 (28.9 %) |
| Tumor type | ||
| nodular | 35 (36.8 %) | 22 (57.9 %) |
| infiltrative | 60 (63.2 %) | 16 (42.1 %) |
| Lobe | ||
| left | 1 (1.1 %) | 3 (8 %) |
| right | 10 (10.5 %) | 8 (21 %) |
| bilobar | 84 (88.4 %) | 27 (71 %) |
| Extrahepatic Metastasis | ||
| no | 86 (90.5 %) | 35 (92.1 %) |
| yes | 9 (9.5 %) | 3 (7.9 %) |
| Lymph Node Metastasis* | ||
| no | 40 (42.1 %) | 12 (31.6 %) |
| yes | 55 (57.9 %) | 26 (68.4 %) |
*
Enlargement of intrahepatic and paraortic lymph nodes on contrast enhanced magnetic resonance imaging or computed tomography
cTACE, conventional trans-arterial chemoembolization; DEB-TACE, drug-eluting beads TACE; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status